News round-up by DDW’s Reece Armstrong for 6-10 June
Antibiotic developments, vaccines for MMR and business expansions are some of the features of this week’s news round-up.
GSK’s vaccine for the prevention of measles, mumps and rubella (MMR) has been approved by the US FDA, the company has announced.
Biotechnology company Nosopharm has reported positive toxicology results for its first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections.
Two life sciences companies have been awarded an €800K grant for their work developing a small molecule therapy for a fast-growing blood cancer.
Artificial intelligence (AI) solutions provider Phesi has developed a digital twin for Cytokine Release Syndrome (CRS) patients following CAR-T therapy.
Solutions provider SMC Ltd has opened a new business offering pharmaceutical development services at the Cambridge Research Park in the UK.